BioSpace News Archive

Sol-Gel Technologies, Ltd. today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

BPGbio announced today the publication of a significant, multi-year research effort titled “ Identification and validation of N-acetylputrescine in combination with non-canonical clinical features as a Parkinson’s disease biomarker panel” in Scientific Reports.

Septerna today announced that the company will present the first preclinical data on the company’s parathyroid hormone 1 receptor (PTH1R) and thyroid stimulating hormone receptor (TSHR) programs at the Endocrine Society’s Annual Meeting (ENDO 2024) held June 1-4 in Boston.

Beaconcure Inc. announces a strategic partnership with Phastar Inc., a global specialist biometrics contract research organization (CRO), to enhance clinical review processes in clinical trials.

mBIOTA Labs today announced the initial study results of their first prospective clinical trial assessing the efficacy of the mBIOTA Elemental™ diet in patients with small intestinal bacterial overgrowth (SIBO), intestinal methanogen overgrowth (IMO), or a combination of the two.

Scorpius Holdings, Inc, an integrated contract development and manufacturing organization, announced a significant expansion of its operational footprint in San Antonio, Texas, with the opening of its new, state-of-the-art storage and testing facility.

Foghorn Therapeutics Inc. announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share, before underwriting discounts and commissions, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock at a price of $5.5099 per pre-funded warrant.

Anokion SA today announced additional favorable safety and efficacy data from the company’s ongoing Phase 1b/2 clinical trial (ACeD-it) evaluating KAN-101 as a treatment for celiac disease.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024 meeting.

OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the Marriott Marquis in New York City.